Q3 Earnings Forecast for Amgen Issued By Leerink Partnrs

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for Amgen in a report issued on Tuesday, August 5th. Leerink Partnrs analyst D. Risinger now forecasts that the medical research company will post earnings per share of $5.13 for the quarter, down from their prior forecast of $5.40. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. Leerink Partnrs also issued estimates for Amgen’s Q4 2025 earnings at $5.00 EPS, FY2025 earnings at $21.11 EPS and FY2026 earnings at $20.32 EPS.

A number of other brokerages have also recently commented on AMGN. William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. Wall Street Zen upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 18th. Bank of America lifted their target price on shares of Amgen from $252.00 to $261.00 and gave the company an “underperform” rating in a research note on Wednesday, July 23rd. UBS Group cut their target price on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a research note on Wednesday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $328.00 target price on shares of Amgen in a research note on Friday, June 27th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $303.76.

Amgen Stock Up 0.0%

Shares of AMGN opened at $284.70 on Thursday. The stock has a market cap of $153.09 billion, a price-to-earnings ratio of 23.28, a P/E/G ratio of 2.46 and a beta of 0.49. The company has a quick ratio of 0.88, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. Amgen has a 12 month low of $253.30 and a 12 month high of $339.17. The company has a 50-day moving average price of $293.20 and a two-hundred day moving average price of $292.48.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%. The business had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same period last year, the business earned $4.97 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year.

Institutional Trading of Amgen

A number of institutional investors have recently bought and sold shares of AMGN. Wealth Preservation Advisors LLC acquired a new position in shares of Amgen in the 1st quarter valued at $25,000. First Pacific Financial grew its holdings in shares of Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock valued at $28,000 after buying an additional 67 shares during the period. CBIZ Investment Advisory Services LLC grew its holdings in shares of Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after buying an additional 85 shares during the period. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the 2nd quarter valued at $27,000. Finally, Pinney & Scofield Inc. acquired a new position in shares of Amgen in the 4th quarter valued at $26,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president owned 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.76% of the company’s stock.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Friday, August 22nd. Amgen’s payout ratio is currently 77.84%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.